Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Assay predicts breast cancer response to tamoxifen and chemotherapy
January 20th, 2005
The Oncotype DX Recurrence Score Assay may predict which breast cancer patients are at risk for distant recurrence and which patients will benefit from tamoxifen or chemotherapy, according to results presented at the 27th Annual San Antonio Breast Cancer Symposium by Soonmyung Paik and colleagues from Genomic Health, Inc., in Redwood City, California. Recurrence score measures the expression of 21 genes (16 directly related to cancer development and five included as reference genes), and converts the measurements into a score ranging from 1 to 100. Based on the recurrence score, patients can be rated as low risk (score less than 18), intermediate...
Source: Women's Health Weekly (2005-01-20)
|
